An overview of Alpivab and why it is authorised in the EU
Alpivab is an antiviral medicine that contains the active substance peramivir. It is used to treat uncomplicated influenza (flu) in adults and children over 2 years. Uncomplicated means that the flu has typical features (such as fever, aches, cough, sore throat and runny nose) and is not made worse by other conditions.
Alpivab : EPAR - Medicine overview (PDF/67.88 KB)
First published: 25/04/2018
Last updated: 25/04/2018
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Biocryst UK Limited
|Date of issue of marketing authorisation valid throughout the European Union||
13/04/2018 Alpivab - EMEA/H/C/004299 - -
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Alpivab is indicated for the treatment of uncomplicated influenza in adults and children from the age of 2 years (see sections 4.4 and 5.1)